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Supportive Care of the 
Leukemic Patient 
Ellis J. Van Slyck, MD* 
The outlook for the patient with leukemia 
or lymphoma has been improved by the 
exponential expansion of basic scientific 
knowledge in physical chemistry and mi-
crobiology, added to much new clinical 
information based on large cooperative 
group studies. Most of this progress derives, 
not from a specific treatment for the disease, 
but from better understanding and use of 
multiple support measures. These include 
the availability of blood components, such 
as red blood cell, platelet and granulocyte 
concentrates, better protective Isolation 
measures, and greater expertise In the rec-
ognition and treatment of bacterial, fungal, 
and viral Infections in immunosuppressed 
patients. In addition, the management of 
associated metabolic disturbances, such as 
hyperkalemia, hyperuricemia, and hyper-
calcemia, is now based on firm ground. A 
review of the major progress In these vari-
ous areas of supportive care comprises this 
essay. 
Presented as part of a symposium on Manage-
ment of Leukemia at Memorial Hospital, South 
Bend, Indiana, March 12, 1975 
* Department of Medicine, Division of Hematol-
ogy 
Address reprint requests to Dr. Van Slyck at 
Henry Ford Hospital, 2799 West Grand Boule-
vard, Detroit Ml 48202 
Improvement in remission rate and length 
of survival overall in acute leukemia can be 
credited in large measure to better manage-
ment of the hemorrhagic complications and 
the infections seen in most of these patients. 
Particularly is this so during the post-treat-
ment phase of cyclic chemotherapy when 
severe marrow aplasia and peripheral pan-
cytopenia become intense. Today roughly 
11 % of patients with acute leukemia die of 
hemorrhage alone, 69% die of infection 
alone, and the remainder die of both factors 
or some other cause.' This essay wi l l at-
tempt a concise review of current measures 
and approaches available in support of the 
patient whose condition is marrow-de-
pressed and immuno log ica l l y compro-
mised. 
1. Blood Cell Component 
Therapy 
The use of whole blood should be re-
stricted to episodes of massive hemorrhage. 
When there is need to support a falling 
hemoglobin level due to unremitting blood 
loss and/or marrow hypoplasia, packed red 
blood cells should be the first choice. Ad-
vantages over whole blood are less total 
volume, and less sodium intake. Sodium 
balance may be critical in the many patients 
who are receiving, concomitantly, cortico-
steroids (Na"*" retention) and carbenicillin 
(high Na^ content). Furthermore, packed 
cells contain less alloimmunizing material 
in the suspending plasma, and, generally, 
patients tolerate packed cells longer than 
whole blood before developing pyrogenic 
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or other reactions. In our experience, in-
creasingly frequent pyrogenic episodes oc-
curring with succeeding packed cell trans-
fusions can often be controlled by removing 
the buffy coat of the packed cells with a 
pipette prior to administration. This obser-
vation suggests that leukocyte or platelet 
antigens are responsible for most of these 
febrile reactions. 
Frozen Stored Red Cells 
Occasionally, when transfusion reactions 
are resistant to the above maneuvers, one 
can use frozen red cells, which are thawed, 
washed, and resuspended in saline. It is 
necessary to wash out the glycerol (a 
cryoprotective agent). These preparations 
are expensive, and the donor red cells are, 
per force, somewhat damaged. Therefore, 
survival in the recipient is shortened. 
Frozen red cells may be the transfusion 
method of choice despite the drawbacks, in 
situations involving very rare blood types 
and severe alloimmunization reactions to 
plasma proteins, white cells or platelets. 
Platelet Concentrates 
It is now practicable to prepare and ad-
minister platelet concentrates (generally in 
numbers equivalent to 4-12 units of donor 
blood, reduced to a volume of 50-150 cc). 
The effective functional life of the donor 
platelet is probably no more than 48 hours, 
and, with succeeding boli of pooled ran-
dom platelets, rapid alloimmunization de-
velops in the recipient. Thus, after three to 
eight platelet transfusions, the progressively 
more rapid destruction of donor platelets in 
the recipient makes their value nil. The best 
practical guide to judging the effectiveness 
of a given bolus of platelets is performing a 
post-transfusion count and observing the 
clinical effect on hemostasis.^ Some on-
cologists have recommended giving pro-
phylactic donor platelets daily or every 
other day, when the platelet count reaches 
levels below 20,000 per cu mm. Others, 
including this author, feel it is better to wait 
for episodes of frank and significant bleed-
ing. In favor of the first position can be cited 
a study in children by Roy,^ who observed a 
26% incidence of major bleeding at platelet 
counts below 10,000 per cu mm. This is a 
significantly greater figure than that seen in 
children receiving both low and high dose 
platelet concentrates daily. Furthermore, it 
cannot be denied that the first manifestation 
of a severe hemorrhagic complication can 
be a fatal cerebral or gastrointestinal hemor-
rhage, occurring too rapidly to be control-
led by platelet transfusions "on demand." 
Ffowever, the rapid development of alloim-
munization to random donor platelets, cou-
pled with long periods of marrow suppres-
sion seen after many courses of chem-
otherapy, makes the "on demand" use of 
platelets superior, in my view. There are 
other hazards in administering platelets be-
sides alloimmunization; such as the trans-
mission of hepatitis virus, cytomegalovirus, 
or toxoplasmosis. Rarely, the transmission 
of bacterial contaminants from platelets 
stored at room temperature as well as graft-
vs-host reactions from lymphocytes present 
in the concentrates have been described in 
severely immunosuppressed recipients. 
When it is possible, there is a greater 
advantage in using HL-A matched donors 
for platelets, matched at least at the four 
major loci." These donors are generally 
siblings of the patient. Parents and children 
of the patient wi l l have two matched loci, 
rarely more, but are better donors than 
random donors. The chances of finding a 
four antigen HL-A match from an unrelated 
donor is one in 10,000 or 20,000. Non-HL-
A platelet specific antigens can produce 
sensitization even in matched siblings. And, 
there is the further problem of " locking i n " 
a donor to a protracted, tedious regime, 
once he or she is identified. 
Platelets may be stored at 4°C or 22°C. 
Those at the colder temperatures require 
warming before administration. Platelets at 
4°C do not survive as well in the recipient as 
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platelets at room temperature, but they ap-
pear to respond to aggregating agents in 
vitro better than those at room temperature. 
In vivo studies also show correction of 
bleeding times by 4°C platelets immediately 
after infusion, but not by 22°C platelets, 
although the latter seem to regain their 
hemostatic properties after a few hours. We 
are currently using 22°C platelets routinely. 
Theoret ica l ly , the use of autologous 
platelets collected from the recipient at a 
previous time in anticipation of later need, 
is the best source. In a few investigative 
studies, these autologous platelets have in-
deed demonstrated their effectiveness.^ 
However, long term preservation, using ei-
ther 5% DSMO or 5% glycerol as cryo-
preservatives, has not been entirely satisfac-
tory. Thawing of platelets and washing out 
of the preservatives prior to administration 
damage the platelets. Current investigative 
work concerns finding optimum rates for 
freezing, optimum freezing temperature, 
best volume of concentrate, best cryo-
preservative, and its best concentration, etc. 
Precollected autologous platelets are not a 
practical tool, at present. 
The use of fresh frozen plasma and pro-
thrombin complex concentrates, such as 
Konyne, have no place in the management 
of leukemic patients. The former might be 
used to correct one or more clotting factor 
deficiencies, should they occur not as a 
result of disseminated intravascular coag-
ulation, but this situation must be rare. 
Prothrombin complex concentrates should 
probably be used only to treat patients with 
Christmas disease. This material probably 
contains a thromboplastic contaminant, 
and its use has produced intravascular co-
agulation and large vessel t h r o m b o s i s . I t 
also is a common source of hepatitis virus. 
The disseminated intravascular coagula-
tion (DIC) syndrome occurs commonly as a 
complication of progranulocytic leukemia. 
Evidence for it, such as decreased fibrin-
ogen and increased fibrin split products, 
should be routinely sought in this disease. 
Because thrombocytopenia may well be 
drug- or leukemia-related, low platelet 
counts may not be a helpful diagnostic sign, 
but, when present, prolongation of the pro-
thrombin time, partial thromboplastin time, 
and decreased factor VIII and V assays are 
indicative of the condition. The syndrome 
occurs frequently as a result of coincident 
septicemia during the course of leukemia. 
In this situation, prompt and vigorous treat-
ment of the infection (to be discussed later) 
is more helpful than is heparin. If severe and 
generalized bleeding is due to DIC, the 
administration of heparin (starting with low 
doses —10,000-15,000 u/d—and increas-
ing cautiously, if necessary) is an accepted 
m a n e u v e r . O b t a i n i n g ser ia l serum 
fibrinogen and fibrin split product assays is 
the best way to monitor the response to 
heparin, in addition to observing clinical 
control of bleeding. 
Granulocyte Transfusions 
Some institutions involved in the aggres-
sive treatment of acute leukemia and the 
lymphomas are coming to the use of gran-
ulocyte concentrates in the management of 
the neutropenic and septic patient. A l -
though our own experience with donor 
granulocytes has been small and disap-
pointing, there is clear evidence of benefit 
in the hands of others." One observation 
seems clear: random donor granulocytes 
have a poor record. One should obtain 
relatives, preferably siblings, as donors. At 
times the urgency of the clinical situation 
may preclude an HL-A matching, at least 
until after the first collection and admin-
istration. The two methods of collection are 
by 1) differential centrifugation and 2) con-
tinuous flow filtration leukopheresis (CEEL). 
The first method involves the use of a blood 
cell separator, and 100% increase gran-
ulocyte yields from the donor can be pro-
cured by administering etiocholanolone 12 
hours priorto donation. Further increases in 
yields can be obtained by using hydroxy-
ethyl stars (HES), a glucopyranone polymer 
derived from waxy sorghum cornstarch. 
This material, introduced into the separator, 
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promotes rouleaux of red cells and thereby 
delineates better the granulocyte layer. By 
use of these techniques, 2.73 x I C gran-
ulocytes per litre of donor blood processed 
was obtained by McCredie et a l . ' In con-
trast, Djerassi,'" using two nylon fiber filters 
in parallel to collect granulocytes and then 
eluting them off the filters in a continuous 
flow system, processed 10-18 litres of blood 
in three hours. The granulocyte yield is 
much greater than by differential centrifuga-
tion, averaging 37.5 x 10' cells. These 
granulocytes have been shown to retain 
normal function, ie, ingestion of bacteria 
and latex particles, and migration to sites of 
infection. However, pyrogenic reactions are 
increased in the recipient as compared to 
separator prepared cells even in HL-A 
matched donors. In favor of CFFL is the 
relatively low cost, and the ease of re-using 
the same donor, since only 30 cc of red 
cells are sacrificed at each donation. As 
methods are refined, we can reasonably 
expect to have useful granulocyte transfu-
sions as adjunctive support to the leukemic 
patient in a few years. 
Plasmapheresis 
Although not strictly pertinent to the topic 
of supportive management of the leukemic 
patient, it is probably valid to mention the 
proven value of plasmapheresis in myeloma 
and lymphoma patients with extreme levels 
of serum globulin. The occurrence of a 
hemorrhagic state due to impairment of 
platelet function or fibrinogen conversion 
by excess globulin and/or manifestations of 
the hyperviscosity syndrome both can be 
satisfactorily controlled with this technique. 
II. Infection 
It is a rare patient with acute leukemia 
who does not become "infected" by bac-
terial or fungal organisms. Often infection 
produces the initial awareness of illness 
which leads to medical care and the diag-
nosis of the leukemia. At other times infec-
tion occurs duringthe course of early chem-
otherapeutic efforts at attaining remission. 
As a rule of thumb, an absolute neutrophil 
count below 500/cu mm, certainly below 
200/cu mm, carries with it almost sure 
promise of bacterial invasion of the host. 
Furthermore, neutropenic patients may fail 
to elicit the expected signs of local inflam-
mation at infected sites, and may not neces-
sarily have significant fever. On the other 
hand, a leukemic patient who suddenly 
shows a fever of 38.5°C ( lOrP) , or more, 
surely has an infection and should be treat-
ed as such with all urgency. Acute leukemia 
per se may produce a low-grade fever, but 
never as high as lOTR Drugs sometimes 
produce this high fever and cause confusion 
in the patient already receiving antibiotics 
or antileukemic agents. Sites of trauma, 
such as the mouth and anal region are 
frequently the portal of entry for infecting 
agents, as is the respiratory tract and skin. 
Local lesions should be sought, since their 
presence may suggest the most likely infect-
ing organism(s). For example, £ coll, and P 
aeruginosa are often cultured from perirec-
tal and rectal abscesses; gram negative bac-
teria and fungi from pharyngitis; Klebsiella 
sp organisms, and fungi from pneumonia; E 
coli from urinary tract infections; and S 
aureus from skin lesions. 
In 90% of cases sepsis was due to either P 
aeruginosa, E col l , or K pneumonia in a 
1968 study at M.D. Anderson Hospital" 
(see table 1). Other institutions vary some-
what as to which are the most prevalent 
organisms causing septicemia. The clini-
cian should be familiar with the local cur-
rent experience in this regard. It is notewor-
thy in a given patient that once an organism 
produces clinical disease which responds to 
treatment, a second episode of infection is 
very likely to be due to this same organism. 
LJnfortunately, there are too many excep-
tions to this rule to be useful in the overall 
therapeutic plan. Acknowledging that it 
may be difficult to recognize sepsis in this 
group of patients, nonetheless, the pro-
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Table 1 
BACTERIAL ORGANISMS PRODUCING 
SEPSIS IN LEUKEMIC PATIENTS 
1) Pseudomonas aeruginosa 4(D% 
2) Escherichia coli 30% 
3) Klebsiella pneumoniae 20% 
4) Staphylococcus aureus 3% 
5) Proteus vulgaris 2% 
6) Others 57o 
Data is derived from unpublished observations 
by GP Bodey, M.D., Houston, Texas, in 1968. 
phylactic use of antibiotics is unwise. It has 
been clearly shown that the longer such a 
patient receives antibiotics, the greater his 
chances of acquiring an infection due to 
resistant organisms. Greene et al reported 
superinfections in patients taking a three-
drug antibiotic treatment, ie, 12%, 25%, 
and 50% after 6, 12, and over-12 days 
respectively.'^ On the other hand, delay in 
starting treatment of septicemia until there 
is cultural proof wil l result in a high per-
centage of failure. 
With these considerations in mind, the 
followingmodus operandi seems most logi-
cal in the management of the acute leuke-
mic patient: At the first clinical clue that 
sepsis is present, cultures of blood, sputum, 
throat, and urine are taken, along with a 
chest x-ray. A three-drug antibiotic regi-
men, consisting of gentamicin, carbenicillin 
and cephalothln is given via a parenteral 
route. There is evidence that carbenicillin is 
more active in the presence of neutropenia 
than the other agents. Furthermore, car-
benicillin and gentamicin seem to be syn-
ergistic in Pseudomonas infections. Gen-
tamic in and cephalo th ln probably work 
synergistically in Klebsiella infections, and 
a l l c o m m o n i n f e c t i n g bac te r i a are 
"covered" by these three drugs. This pro-
gram is followed for eight days unless a 
specific organism is recovered which would 
dictate an appropriate change in the regi-
men. For example, recovery of an anae-
robic Bactero/des resistant to pen ic i l l in 
might warrant a change to clindamicin.'^ If 
the organism is not recovered, and the 
patient remains clinically septic, all anti-
biotics are discontinued around the eighth 
day, and additional cultures obtained after 
48 hours. However, many patients respond 
promptly to this program. Others survive 
long enough so that neutrophils repopulate 
the circulation if marrow recovery occurs. 
Frequently, all signs of sepsis disappear 
when the polymorphs return. Relapses, oc-
curring with subsequent vagaries of the 
disease or with cyclic chemotherapy re-
quire repetition of the same prompt attack. 
Because of the frequency of monilial 
stomatitis, pharyngitis, and esophagitis, par-
ticularly in neutropenic patients receiving 
corticosteroids, mycostatin oral suspension 
is prescribed prophylactically during the 
periods of risk. This practice does not seem 
to create any new problems and is effective 
in controlling and/or eradicating oral can-
didiasis. Other important preventive mea-
sures include avoidance of intravenous 
catheters, changing intravenous needles ev-
ery 48 hours, and changing intravenous 
tubing daily. Also, one should avoid using 
urinary catheters or any other invasive pro-
cedure not clearly of ultimate benefit to the 
patient. Skin care is of unusual importance 
in this clinical setting. Prompt attention to 
even the most innocuous-appearing lesion, 
t r imming finger and toe nails, regular 
bathing, avoiding wetness and maceration 
of skin, all must be included in the nursing 
regimen. The bacterial burden to the patient 
can be reduced to a significant degree by a 
private room and by practicing a simple 
form of reverse isolation. We require per-
sonnel attending the patient to use gown, 
mask, and gloves. Potential sources of 
pathogens such as respiratory equipment, 
ice machines, bath tubs, etc., should be 
monitored by periodic culturing. 
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Table 2 
NON-BACTERIAL INFECTIONS 
SEEN IN LEUKEMIC PATIENTS 
Candidiasis 
Aspergillosis 
Mucormycosis 
Varicella-Zoster 
Cytomegalovirus disease 
Pneumocystis Carinii Pneumonia 
Toxoplasmosis 
Viral hepatitis 
Cryptococcal meningitis 
Fungal and Protozoal 
Infections 
Table 2 is an incomplete list of nonbac-
terial causes of infection seen with increas-
ing frequency in immunosuppressed pa-
tients. These include fungal, protozoal and 
viral organisms. 
Candidiasis in pharynx and urine gener-
ally represents superficial infection, but 
substernal pain and dysphagia may indicate 
invasive esophagitis. These symptoms in the 
presence o f o the r e v i d e n c e of o r o -
pharyngeal thrush should virtually establish 
the diagnosis, although esophagograms, 
esophagoscopy, and biopsy are decisive in 
quest ionable cases. I n the immunosup-
pressed neutropenic patient with acute leu-
kemia, late stage chronic leukemia or lym-
phoma, Candida organisms, (ie, albicans, 
troplcalis, and other species) are the most 
common fungal offenders. Their presence 
should be suspected if a patient fails to 
recover satisfactorily from antibacterial 
therapy or has a late febrile relapse. Since 
the advent of aggressive chemotherapy in 
acute leukemia, candidiasis has strikingly 
increased. Pseudomycelial forms of Can-
dlda in the urine suggest the presence of the 
disseminated form of the disease while find-
ing Cand/da in blood or marrow cultures, in 
the absence of i ndwe l l i ng intravenous 
catheters, v i r tua l ly establishes the diag-
nosis. Despite its toxicity, amphotericin B 
should be used in this latter circumstance. 
5-Fluorocytosine, a new oral ant i fungal 
agent, has been disappointing in dissemi-
nated candidiasis in the compromised host, 
although synergism with amphotericin B 
has been described.'" 
The second most common fungus invad-
er in the leukemic patient, also with in-
creasing incidence is Aspergillus, rarely rec-
ognized ante-mortem and even less often 
treated successfully. This species generally 
attacks the respiratory tract. Chest roent-
genograms show a variety of pulmonary 
abnormalities in already severely ill pa-
tients. At autopsy, widespread involvement 
of the gastro-intestinal tract, brain, liver and 
kidney is often found. More aggressive diag-
nostic efforts, such as bronchial brushing, 
closed needle aspiration, or even open lung 
biopsy, may make it possible to recognize 
invasive disease in time to render effective 
antimycotic therapy with amphotericin B. 
Mucormycosis should be considered in 
chronically ill, neutropenic, immunologi-
cally deprived individuals who demonstrate 
in addition the triad of orbital cellulitis, 
sinusitis, and diabetes mellitus (generally 
poorly controlled). Diagnosis requires a bi-
opsy of infected tissue from skin, palate, or 
lung since ord inary fungus cultures are 
rarely posftive. 
Cryptococcosis and histoplasmosis are 
rarely seen in acute leukemia, but continue 
to occur in the late stages of chronic leuke-
mia and lymphoma. Patients who seem to 
be failing in a nondescript way, with or 
without fever, and without obvious progres-
sion of their basic hematologic disease, may 
have one of these latter two fungal diseases. 
In addition, disseminated toxoplasmosis or 
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Pneumocyst/'s carinii pneumonia are occa-
sionally responsible for the same clinical 
picture, although Pneumocyst/s is almost 
always accompanied by dry cough, tachy-
pnea, and objective signs in the chest. 
Cryptococcus neoformans meningitis, 
when present, only yields a 50% positivity 
on India ink preparations of the cerebrospi-
nal fluid. One should always culture the 
spinal fluid as well as the sputum and urine 
in suspected cases. Complement fixation or 
latex agglutination tests of the spinal fluid 
are also helpful. Histoplasmosis, of all the 
fungi, is most successfully cultured from 
blood or bone marrow with positive results 
in 50% of disseminated cases." Should the 
signs of Addison's disease occur during the 
course of chronic leukemia or lymphoma, 
the most likely causes are histoplasmosis or 
myleran toxicity. Disseminated or adrenal 
tuberculosis has become less common in 
recent years. Biopsy of oral ulcers may 
disclose the presence of the typical-appear-
ing fungus. The combination of ampho-
ter ic in B and 5-Fluorocytosine is occa-
sionally successful against cryptococcosis 
and histoplasmosis. 
Toxoplasma gondii disseminates in im-
munodepressed hosts, producing a serious 
preterminal condition. Because of central 
nervous system (CNS) involvement, mental 
symptoms, cranial nerve palsies and motor 
paresis occur. Although rising titres of Tox-
oplasma antibodies are diagnostic, it may 
be quicker to obtain a biopsy of a lymph 
node, where typical pathologic changes 
can be recognized. Treatment current ly 
g i v e n is t h e c o m b i n e d use o f 
pyrimethamine and sulfadiazine for four 
weeks. 
To recover the organisms of Pneu-
mocystis carinii, one must generally per-
form open lung biopsy although a few 
reports of success with bronchial brushings 
and tracheal aspirations are avai lable. 
Treatment for this protozoan organism in 
established cases is pentamidine isethionate 
for two weeks. Experience at the National 
Cancer Institute indicates about a 50% 
clinical recovery overall, and 80% in pa-
tients who received treatment for 7 days or 
more.' 
Viral Infections 
Chronic lymphocytic leukemia and lym-
phoma patients are particularly prone to 
some, but not all, viral disease. The pre-
dominant culprits are herpes viruses, in-
c lud ing varicel la-zoster, simplex, and 
cytomegalovirus. In addition, vaccinia and 
measles produce more severe clinical dis-
ease in these patients. As a general rule it is 
wise to avoid using any vaccine which 
contains live and/or attenuated virus in 
potentially immunosuppressed subjects. 
Varicella-zoster either in its typical der-
matome or disseminated distribution is easi-
ly recognized. If deemed necessary, a 
Tzank test can be performed to confirm the 
etiology. This consists of finding, under light 
microscopy, intranuclear inclusions in mul-
tinucleate giant cells from scrapings taken 
from the base of vesicles, stained by the 
Giemsa method. Both the local and dis-
seminated (chicken pox) form of the disease 
are more severe, the latter being life-threat-
ening, as is the pneumonic form. ZIG (zos-
ter immune globulin) is an effective passive 
suppressant of v a r i c e l l a in exposed 
children, but it must be given within 72 
hours of exposure. Since zoster is thought to 
be a reactivation of a dormant varicella 
virus in adults and, clearly, prophylaxis is 
not feasible, ZIG would appear to be use-
less in the latter. Furthermore, the large 
dose (0.5 ml/kg) is impracticable. In adults 
who develop severe herpes, the use of 
adenine arabinoside (Ara-A) has recently 
shown promise. Cytosine arabinoside (Ara-
C) and idoxyuridine (lUDR) have not been 
effective, although the latter (lUDR) is of 
proven value in herpetic keratitis. Ara-A in 
the recommended dosage, 10 mg/kg/day x 
5 days in continuous intravenous drip, is 
less toxic to marrow and immuno-suppres-
sive than Ara-C and other antimetabolites. 
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Wfth regard to herpes simplex (hominis) 
infection, suffice it to say that the local skin 
or mucous membrane lesion may develop 
an extensive area of cellulitis in compro-
mised hosts. Occasionally, one of these 
patients wil l develop an atypical indolent 
encephalitis which mimics progressive mul-
tifocal leukoencephalopathy. Brain biopsy 
is required to establish the etiology of the 
CNS symptoms. A study to evaluate treat-
ment with Ara-A is underway,"" but the 
problem of securing a patient population 
with proven herpes encephalitis is obvious. 
lUDR has been found unacceptably toxic in 
this condition.'^ 
The occurrence of clinical symptoms due 
to cytomegalovirus does not seem to be 
more prevalent in leukemia and lymphoma 
patients. However, the manifestations are 
so variable that the present status of this 
entity is vague at best. A prospective study 
at the National Cancer Institute tried to 
clarify points regarding the significance of 
virus excretion in throat or urine in relation 
to cryptogenic fever, rash, or pneumonitis, 
and also evaluate the presence of hemag-
glutinating antibody and complement-fix-
ing antibody.'" Patients with severe pneu-
monitis, rash and fever, with demonstrated 
virus in throat or urine, and a fourfold 
antibody rise should probably receive anti-
viral agents, such as Ara-A or ILIDR. 
Because of the likelihood of severe local 
reaction or general ized d isseminat ion, 
smallpox vaccination should be avoided in 
patients with chronic lymphocytic leukemia 
or lymphoma. Nonetheless, despite this ad-
monition, vaccinia gangrenosa, eczema 
vaccinatum, or generalized vaccinia wil l 
continue to occur among the unwary. VIG 
(vaccinia immune globulin), in 0.6 ml/kg 
intramuscular dosage, is sometimes suc-
cessful in controlling these often fatal man-
i fes ta t ions. " Marboran, a th iosemicar-
bazone, has also been shown to be effec-
tive. The drug is taken orally in doses of 200 
mg/kg/daily for four days. 
The immunosuppressed patient, if in-
fected with rubeola virus, may succumb to 
a severe pneumonic process. This virus, 
which can be recovered from normal indi-
viduals only up to 48 hours after disap-
pearance of the rash, has been shown to 
persist in leukemic patients' respiratory 
tracts for long periods. Successful passive 
immunizat ion w i th commerc ia l gamma 
globulin in a dose of 0.25 ml/kg can be 
accomplished if given within 48 hours of 
exposure, and modification of the severity if 
given within five days of exposure. 
Hepatitis B is an on-going problem in the 
management of leukemia and lymphoma 
patients, because of the usual high transfu-
sion requirement. The incidence decreases 
if only healthy, Australia antigen-negative 
volunteers are used as a source of blood for 
transfusion in contradistinction to commer-
cial donors. Although gamma globulin in-
tramuscularly can protect against hepatitis 
A, it is not predictably effective against type 
B exposures. Furthermore, it is impractica-
ble to carry out long term prophylaxis with 
this passive immunization method. Current 
research is pointing the way toward inac-
fivation of the virus in the donor blood prior 
to its administration. A 75% reduction in 
the incidence of icteric hepatftis has been 
described by incubation of donor blood 
with gamma globulin.^" Also, active immu-
nization wfth a vaccine consisting of a heat-
inactivated Australia antigen is under trial. 
In treating the patient wfth viral hepatitis, it 
is best to refrain from the use of cor-
ticosteriods early in the clinical course, 
since this therapy has been shown to be 
associated wfth an increased incidence of 
chronic sequelae and the Australia antigen 
carrier state. 
III. Metabolic Abnormalities 
In acute leukemia, the most common 
metabolic disturbances are shown in Table 
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Table 3 
METABOLIC DISORDERS ASSOCIATED 
W ITH LEUKEMIA AND LYMPHOMA 
1) Positive Na balance, fluid overload 
2) Hyperkalemia and Hypokalemia 
3) Hyperuricemia 
4) Hypercalcemia 
drugs may be responsible for significant 
ionic shifts. For the present, it is well to 
realize that, although hypokalemia may be 
present before any treatment of the leuke-
mia is begun, most often it appears some-
time during the complex post-treatment 
period. It makes a major contribution to the 
patient's morbidity. The condition is gener-
ally slow to respond to potassium replace-
ment, but obviously the attempt should 
be made, if renal function is grossly satis-
factory. 
3. The occurrence of hyponatremia and 
hypochloremia as a result of excessive 
losses in the gastrointestinal efflux requires 
appropriate replacement by parenteral flu-
ids. However, conversely, one often sees 
hypernatremia and/or vascular congestion 
from excessive sodium intake, associated 
with large doses of carbenicillin in conjunc-
tion with the need for blood products and 
intravenous chemotherapy. 
Hyperkalemia and Hypokalemia 
Recently the findings of hyperkalemia^' 
and hypokalemia^'' have been described 
during the course of acute leukemia. The 
hyperkalemic state has been explained, at 
least theoretically, by the release of po-
tassium from leukemic cells but, paradox-
ically, hypokalemia has also been found in 
the presence of high total body potassium." 
A renal tubular defect, possibly associated 
with excess lysosyme excretion seen in 
monocytic and myelomonocytic leukemia 
may account for a high potassium excretion 
rate and a consequent low serum level but 
the explanation is almost certainly more 
complex. The antibiotics gentamicin and 
carbenicillin may induce urinary potassium 
loss. By altering cell membranes, cytotoxic 
Hyperuricemia 
Hyperuricemia occurs frequently in pa-
tients with both chronic and acute leukemia 
of all cell types. The serum uric acid level 
fluctuates with disease activity and with the 
state of renal function. Treatment with radi-
ation or cytotoxic drugs, particularly in the 
presence of a high tumor cell mass, can be 
expected to produce an increase in the 
serum level. It is also a burden on the renal 
mechanism for excretion of urates, whether 
the pretreatment serum uric acid level was 
elevated or not. The development of acute 
renal failure as a result of uric acid nephro-
pathy is an acknowledged and dreaded 
complication of this urate overload. Yet, 
despite its documentation in the literature, it 
must be quite rare, judged by the author's 
exper ience. Nonetheless, it is accepted 
practice to give allopurinol to the patient 
wfth elevated serum uric acid or to the 
patient wfth high tumor cell mass in whom 
one anticipates a rapid cell kill. An inhibitor 
of xanthine oxidase, allopurinol protects the 
serum and kidneys from a large urate load. 
But, it is still wise to alkalinize the urine and 
push f luids in con junc t ion w i t h radi-
otherapy and/or chemotherapy since there 
is the possibility of producing xanthine cal-
culi with these treatment modalities. Al-
lopurinol is excreted by the kidney and the 
dose should be reduced in the presence of 
renal failure. The average dose of 300-600 
mg/day is reduced to 200 mg for a 
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creatinine clearance of 10 ml/min. High 
doses (600-800 mg) are given just prior to 
major treatment thrusts. One should also be 
aware that the interaction of allopurinol 
wfth sorne chemotherapeutic agents, eg, 
cyclophosphamide, results in greater mar-
row depression than with the latter alone. 
Obviously, the occurrence of renal shut-
down, in a clinical setting which suggests 
uric acid nephropathy, would be managed 
by the measures usually employed, no mat-
ter what the underlying cause; ie, fluid 
intake adjusted to maintain normal hydra-
tion (insensible losses plus urine output), 
allopurinol in reduced dosage to adjust for 
impaired output, and alkalinization. Hemo-
dialysis would be preferable to peritoneal 
dialysis, should uremia supervene. 
Hypercalcemia 
Acute and chronic leukemia are rarely, if 
ever, accompanied by a pathologic degree 
of hypercalcemia. On the other hand, the 
condition occurs fairly commonly in un-
controlled myeloma (10%-20%), and occa-
sionally in lymphomas or other malignan-
cies in which bony involvement is a clinical 
feature. Indeed, the presence of hyper-
calcemia may alert the clinician to an other-
wise silent spread of disease to the bones. 
The symptoms of hypercalcemia are non-
specific, but they are suggestive to the alert 
physician: lethargy, depression, constipa-
tion, anorexia, and even nausea and vomit-
ing. The patient is generally dehydrated and 
shows obtunded or absent deep tendon 
reflexes. Frequently, there is an associated 
hyperuricemia with or wfthout variable de-
grees of azotemia. Measures directed to-
ward correction of the hypercalcemia can 
render a very gratifying improvement in the 
patient's well-being as well as in other 
biochemical abnormalities. On the other 
hand, untreated prolonged hypercalcemia 
leads to irreversible renal failure, metastatic 
calcifications, cardiac arrhythmias, shock 
and death. Therefore, we should consider 
hypercalcemia (above 11.5 mg %) as a 
medical emergency, requiring the following 
corrective measures in decreasing order of 
priority. 
1) Rehydrate with adequate fluid replace-
ment to yield a daily urine output of 3 to 4 
litres. 
2) Administer furosemide (Lasix) follow-
ing inftial rehydration. This agent is par-
ticularly effective in inducing calcium ex-
cretion, since it acts to block tubular reab-
sorption of sodium (and therefore, calcium 
at the same site). 
3) Give high dose corticosteriods which 
promptly lower the serum calcium in multi-
ple myeloma patients, less predictably so in 
other cancer patients. The mechanism of 
action is thought to be through decreasing 
bone absorption. 
4) If the first three measures are ineffec-
tual, one should use mithramycin in a single 
intravenous injection of 25 ug/kg." This is 
far below the anti-tumor dose and should 
not significantly affect marrow function. It 
also acts by inhibiting bone absorption, and 
a favorable change in serum calcium is 
generally observed within 24 to 48 hours. 
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